Nicked β2-glycoprotein I binds angiostatin 4.5 (plasminogen kringle 1-5) and attenuates its antiangiogenic property

Blood

Volumn 114, Issue 12, 2009, Pages 2553-2559

  Nakagawa, Hisako ^a   Yasuda, Shinsuke ^a   Matsuura, Eiji ^b   Kobayashi, Kazuko ^b   Ieko, Masahiro ^c   Kataoka, Hiroshi ^a   Horita, Tetsuya ^a   Atsumi, Tatsuya ^a   Koike, Takao ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; ANGIOSTATIN 4.5; BETA2 GLYCOPROTEIN 1; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; ANGIOSTATIN4.5, HUMAN; PLASMIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ARTERY ENDOTHELIUM; ARTICLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; AORTA; CELL CULTURE; CYTOLOGY; FIBROBLAST; METABOLISM; PHYSIOLOGY; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; AORTA; BETA 2-GLYCOPROTEIN I; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FIBROBLASTS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PLASMIN; UMBILICAL VEINS;

EID: 70350509576     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-12-190629     Document Type: Article

References (30)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267(16):10931-10934.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27-31.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353-364. (Pubitemid 26272076)
4. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79(2):315-328. (Pubitemid 24324921)
5. Cao Y, Ji RW, Davidson D, et al. Kringle domains of human angiostatin: characterization of the antiproliferative activity on endothelial cells. J Biol Chem. 1996;271(46):29461-29467. (Pubitemid 26382666)
6. Gately S, Twardowski P, Stack MS, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A. 1997;94(20):10868-10872. (Pubitemid 27430827)
7. Soff GA. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev. 2000;19(1):97-107.
8. Cao R, Wu HL, Veitonmaki N, et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-K5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci U S A. 1999;96(10):5728-5733. (Pubitemid 29234686)
9. Soff GA, Wang H, Cundiff DL, et al. In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna. Clin Cancer Res. 2005;11(17):6218-6225. (Pubitemid 41262951)
10. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335(8705):1544-1547. (Pubitemid 20189625)
11. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87(11):4120-4124. (Pubitemid 20217993)
12. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990;336(8708):177-178. (Pubitemid 20225005)
13. Hughes GR. The antiphospholipid syndrome: ten years on. Lancet. 1993;342(8867):341-344.
14. Hunt JE, Simpson RJ, Krilis SA. Identification of a region of β2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci U S A. 1993;90(6):2141-2145. (Pubitemid 23078581)
15. Horbach DA, van Oort E, Lisman T, Meijers JC, Derksen RH, de Groot PG. β2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost. 1999;81(1):87-95. (Pubitemid 29041656)
16. Itoh Y, Inuzuka K, Kohno I, et al. Highly increased plasma concentrations of the nicked form of β2 glycoprotein I in patients with leukemia and with lupus anticoagulant: measurement with a monoclonal antibody specific for a nicked form of domain V. J Biochem (Tokyo). 2000;128(6):1017-1024. (Pubitemid 32011573)
17. Yasuda S, Atsumi T, Ieko M, et al. Nicked β2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood. 2004;103(10):3766-3772. (Pubitemid 38596293)
18. Yasuda S, Morokawa N, Wong GW, et al. Urokinase-type plasminogen activator is a preferred substrate of the human epithelium serine protease tryptase epsilon/PRSS22. Blood. 2005;105(10):3893-3901. (Pubitemid 40656134)
19. Wenger A, Kowalewski N, Stahl A, et al. Development and characterization of a spheroidal coculture model of endothelial cells and fibroblasts for improving angiogenesis in tissue engineering. Cells Tissues Organs. 2005;181(2):80-88.
20. Chen Y, Wei T, Yan L, et al. Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model. BMC Genomics. 2008;9:264. (Pubitemid 351895450)
21. Suzuki Y, Komi Y, Ashino H, et al. Retinoic acid controls blood vessel formation by modulating endothelial and mural cell interaction via suppression of Tie2 signaling in vascular progenitor cells. Blood. 2004;104(1):166-169. (Pubitemid 38879853)
22. Guedez L, Rivera AM, Salloum R, et al. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol. 2003;162(5):1431-1439. (Pubitemid 36512825)
23. Caldas H, Fangusaro JR, Boue DR, Holloway MP, Altura RA. Dissecting the role of endothelial SURVIVIN DeltaEx3 in angiogenesis. Blood. 2007;109(4):1479-1489. (Pubitemid 46239579)
24. Chang PC, Chang YJ, Wu HL, et al. Mutation of human plasminogen kringle 1-5 enhances antiangiogenic action via increased interaction with integrin αVβ3. Thromb Haemost. 2008;99(4):729-738.
25. Moser TL, Kenan DJ, Ashley TA, et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A. 2001;98(12):6656-6661.
26. Veitonmä ki N, Cao R, Wu LH, et al. Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis. Cancer Res. 2004;64(10):3679-3686.
27. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol. 2001;152(6):1247-1254. (Pubitemid 34280181)
28. Beecken WD, Engl T, Ringel EM, et al. An endogenous inhibitor of angiogenesis derived from a transitional cell carcinoma: clipped β2-glycoprotein-I. Ann Surg Oncol. 2006;13(9):1241-1251. (Pubitemid 44440426)
29. Sakai T, Balasubramanian K, Maiti S, Halder JB, Schroit AJ. Plasmin-cleaved β2-glycoprotein 1 is an inhibitor of angiogenesis. Am J Pathol. 2007;171(5):1659-1669.
30. Yu P, Passam FH, Yu DM, Denyer G, Krilis SA. Beta2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. J Thromb Haemost. 2008;6(7):1215-1223. (Pubitemid 351859131)